A federal court in New Jersey has issued a new Order setting forth a number of deadlines for Nexium lawsuits and other legal claims involving the alleged link between proton pump inhibitors and serious kidney side effects.
At least 315 proton pump inhibitor lawsuits are pending in the U.S. District Court, District of New Jersey, all of which were filed on behalf of patients who claim that their use of Nexium, Prilosec, PrevAcid, and other drugs in this class led to the development of:
Product liability claims involving proton pump inhibitors and kidney injuries began to mount in early 2015, after several studies suggested that their long-term use could lead to serious renal injury. Plaintiffs claim that the drugs’ manufacturers knew of these risks for years, and had in fact received hundreds of reports linking their products to kidney failure and other kidney complications, yet failed to provide patients and doctors with appropriate notification of the danger.
Earlier this year, the U.S. Judicial Panel on Multidistrict Litigation (JPML) centralized all federally-filed proton pump inhibitor lawsuits alleging kidney injuries in the District of New Jersey, so as to to allow the docket to undergo coordinated discovery and other pretrial proceedings.
Court documents indicate that the litigation convened its most recent Case Management Conference on November 8th. On November 16th, the Court issued its 5th Case Management Order, which set forth a number of new deadlines, including:
The federal proton pump inhibitor litigation will convene that conference on December 18, 2017 at 1:00 p.m.